Tech Company Financing Transactions
Euclises Pharmaceuticals Funding Round
Private investors participated in a $1.2 million venture round for Euclises Pharmaceuticals. The round was recorded on 12/3/2016.
Transaction Overview
Company Name
Announced On
12/3/2016
Transaction Type
Venture Equity
Amount
$1,216,913
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed. 5 investors participated in the offering. The amount may include options, warrants or other securities. Contact technology company for investment details, if applicable. Not an offer or solicitation for the sale of securities or debt. SEC regulatory filing.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
4320 Forest Park Ave. 304
St. Louis, MO 63108
USA
St. Louis, MO 63108
USA
Phone
Website
Email Address
Not Recorded
Overview
Euclises Pharmaceuticals, Inc. researches, develops, and commercializes medicines in the field of inflammation and oncology. Euclises Pharmaceuticals, Inc. was formerly known as Talley NewCo, Inc. The company was incorporated in 2011.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Bobby Sandage
Chief Financial Officer
Kathleen Beckmann
Chief Scientific Officer
John Talley
Browse more venture capital transactions:
Prev: 12/3/2016: SQZ Biotechnologies venture capital transaction
Next: 12/3/2016: Appier venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from publicly available VC deal announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs